American International Group AIG

Reference table

1. What it is

American International Group (NYSE: AIG) is a ~100-year-old global insurer (founded 1919) that, after a multi-year restructuring, is now effectively a pure-play property-casualty (P&C) / General Insurance underwriter. It sells commercial and specialty coverage — general liability, property, workers' comp, D&O, cyber, aerospace, marine, environmental, trade credit — plus personal lines (auto, home, high-net-worth, travel, warranty). The old Life & Retirement business (now the separately listed Corebridge Financial) has been deconsolidated and steadily sold down; AIG's Corebridge stake was reduced to just 5.6% by Q1'26. Fiscal year ends December 31. CEO: Peter Zaffino.

Revenue mix (from filings):

• By segment (FY2024, last full segment disclosure): essentially all General Insurance — $27.7B, with small corporate/reconciling items. The Life & Retirement line that used to be ~40% of revenue is gone from the consolidated segment reporting. AIG is today a P&C monoline in all but name.
• By geography (FY2025): International $14.1B (53%) · North America $12.7B (47%) — a genuinely global commercial book, more balanced than most US insurers. This is a diversification strength, though it adds FX translation noise (Q1'26 NPW was +24% reported but +18% constant-dollar).

The strategic story is simplification complete → discipline and capital return: a leaner cost base, a sub-90% combined ratio, aggressive buybacks (share count down from ~600M to ~533M over the past year), and a dividend up 10%+ for four straight years. In Q1'26 AIG also took a 35% stake in Convex Group (a specialty (re)insurer) and a 9.9% stake in Onex — a bolt-on into specialty underwriting.

2. The expert thesis (traceable)

There is essentially no direct AIG expert coverage in the Synthos KB. total_claims = 1, and that single claim is tangential:

• We Study Billionaires (we_study_billionaires-UoNHdafdlRo:592abe8bb9, bullish, conviction 75, 2026-01-10): "Tail-risk insurance (Fairfax's CDS pre-GFC) buys time, credibility and optionality; systemic risk is highly correlated and hits when least expected." This is a claim about the insurance/tail-risk business model — using Fairfax's pre-crisis CDS hedges as the illustration — not a direct AIG bull case. It is thematically relevant (AIG is a large systemic insurer and 2008 is literally its own cautionary history) but it does not underwrite a price target or a franchise thesis on AIG specifically.

Honest disclosure: with only one, tangential claim, this verdict is fundamentals- and quant-driven, not conviction-panel-driven. We are not going to manufacture a panel that does not exist. The bull/base/bear below rest entirely on the reported financials, the analyst estimate set, and standard P&C valuation — not on borrowed conviction. Where the Street sits (a Hold, 15 Buy / 25 Hold / 1 Sell) is more informative here than our near-empty KB, and we treat it as such.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range, and the scores above summarize them.

Synthos fair value = the base case, ~$88 (+11%), with the full $63–$108 span as the honest range. Our base sits just above the Street's $84.17 consensus and slightly below its $92 high — i.e. we largely agree with the Street here (a cheap stock with modest, discipline-dependent upside), which is appropriate given we have no differentiated KB edge on this name. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). AIG is neither — it is a mature value/turnaround insurer:

• Forward growth: revenue is roughly flat-to-low-single-digit (analyst FY26E revenue ~$29.3B vs FY25 $26.8B, partly a definitional/premium-recognition shift); EPS CAGR FY25→FY28E ~11% ($7.04 → $9.60), a chunk of which is share-count reduction, not organic earnings growth (diluted shares fell from ~599M to ~542M year-over-year).
• Acceleration (the 2nd derivative) is negative: EPS growth +14.6% (FY26E) → +10.6% (FY27E) → +7.5% (FY28E). Growth is slowing, the opposite of an exponential.
• Room to run: there is no TAM optionality story here. Global commercial P&C is a mature, competitive, cyclical market; AIG grows with rate and the underwriting cycle, not with a secular platform. Its edge is discipline and capital return, not expansion into a new market.
• Reinvestment runway: AIG returns capital rather than reinvesting for growth — $760M returned in Q1'26 alone ($519M buybacks + $241M dividends). That is exactly right for a mature insurer, but it is the signature of a compounder-via-buyback, not an exponential.

Exponential Potential: Low (2/10). Own AIG, if at all, for cheapness + a growing dividend + buyback-driven EPS accretion — never for a fast multibagger. Honest framing: this is a value/income satellite, structurally the opposite of a Synthos flagship exponential.

5. Financials (real numbers — FMP annual/quarterly + Q1'26 earnings release)

• The headline is underwriting quality, not revenue. For an insurer, the number that matters is the combined ratio (claims + expenses ÷ premiums; under 100% = underwriting profit). Q1'26 GI combined ratio 87.3%, an 850bp year-over-year improvement; accident-year combined ratio as adjusted 86.6%. Underwriting income more than tripled to $774M. This is the core of the bull case and it is real.
• Premiums: Q1'26 net premiums written $5.6B, +24% reported / +18% constant-dollar, driven by North America Commercial +36% and boosted by the Convex transaction and favorable reinsurance renewals.
• Earnings: Q1'26 AATI (adjusted after-tax income) $2.11/diluted share, +80% YoY; GAAP net income $763M ($1.41/sh). FY25 GAAP net income ~$3.1B, EPS $5.48 ($5.43 diluted). Note the messy GAAP history (FY24 bottom-line net income was distorted by the Corebridge deconsolidation) — use AATI and combined ratio, not headline GAAP, to judge this business.
• ROE: reported ROE 7.5%, Core Operating ROE 12.2% in Q1'26 — improving but still only low-double-digit. This is the honest ceiling on the quality score: a 12% ROE insurer is fine, not elite.
• Net investment income: $712M (down 36% YoY on Corebridge/equity fair-value marks) but +8% to $915M on an adjusted APTI basis — the underlying investment book is fine; the GAAP line is noisy.
• Balance sheet: total debt ~$9.2B, net-debt/EBITDA 0.99×, debt/total-capital 18.2%, book value/share $75.82. Investment-grade (FMP letter rating A-), conservatively levered for an insurer.
• Capital return: $760M returned in Q1'26; FY25 buybacks $5.8B + dividends ~$1.0B. Dividend raised to $0.50/quarter (fourth straight year of 10%+ hikes), ~2.3% yield.

6. Valuation — cheap, and that's the point

On every standard lens AIG is inexpensive: 13.9× trailing EPS, 9.8× FY26E, 8.9× FY27E, 1.06× book value (P/B just above 1 is the classic "market barely believes the ROE" tell for an insurer), EV/EBITDA 6.4×, free-cash-flow yield ~8.4%, dividend yield ~2.3%. Price-to-book of ~1.06× against a 12% core ROE implies the market is skeptical the underwriting improvement is durable — which is precisely the debate. If the sub-90% combined ratio holds and core ROE stays ~12%, a 1.2–1.4× book multiple (≈$90–105) is defensible; if it reverts, ~1.0× book (≈$76) is the floor. Street targets (context): consensus $84.17, high $92, low $80 — a tight band around today's price, consistent with a Hold rating (15 Buy / 25 Hold / 1 Sell). Our ~$88 base is within a rounding error of the Street; we have no KB edge to justify diverging. Not a growth buy; a cheap-insurer-if-discipline-holds buy.

7. Technicals (from the FMP tech block)

• Trend: neutral-to-weak. $79.39 sits just above the 50-DMA ($75.74) but roughly at/just above the 200-DMA ($77.53) — no clean uptrend. MACD mildly positive (+0.32).
• Location: −8.3% off the 52-week high ($86.59), +10.4% off the 52-week low ($71.89); max drawdown from peak ~−9.5%. Mid-range, not a breakout.
• Momentum: RSI(14) 65 — firm but not overbought (<70); the +3.7% move on the latest session lifted it toward the top of its range.
• Relative strength (the tell, and it's a red flag): AIG is −7.5% over 12 months while SPY is +20.6% and QQQ +30.3% — a ~28-point lag versus the market over a year. Even 6-month (−7.8% vs SPY +8.4%) is negative. Only the 3-month (+5.1% vs SPY +13.7%) shows life, and it still lags.
• Read: technicals do not confirm a bull thesis — this is a persistent laggard that is cheap partly because it has underperformed. That can be a value setup, but there's no momentum tailwind. No urgency to chase; a value buyer can be patient.

8. Moat & competitive position

AIG's "moat" is modest and of the P&C variety: scale, a global commercial/specialty license footprint, underwriting data, and brand/relationships with large corporate risk managers. These are real but not wide — commercial P&C is a competitive, cyclical, largely commoditized market where pricing power comes and goes with the underwriting cycle (currently favorable/"hard" in commercial lines, which is a tailwind but a cyclical one). AIG's genuine recent achievement is operational: getting the combined ratio from the high-90s/100s of its troubled years down to 87%. That's execution, not a structural moat. The Convex stake is an attempt to add specialty-underwriting scale.

Peer set (FMP-listed, market cap): The Hartford (HIG) $37.8B — the closest US commercial-P&C comp; Arch Capital (ACGL) $35.7B — specialty/reinsurance; plus the life/multiline names the FMP peer list groups it with (MetLife $57.9B, Prudential $39.2B, Manulife $68.7B, Sun Life $44.1B, Ameriprise $44.0B, Banco Santander Brasil). Against HIG and ACGL, AIG trades at a discount to book and to forward earnings — the market is pricing it as the lower-quality, higher-execution-risk name in the group, which the 12% ROE (vs peers' mid-to-high teens) broadly justifies. The bull case is that the gap narrows as discipline proves durable.

9. Management, capital allocation & guidance

• Capital allocation: disciplined and shareholder-friendly — $760M returned in Q1'26 ($519M buybacks ≈ 7M shares + $241M dividends), on top of $5.8B of FY25 buybacks. Share count down ~10% year-over-year. Dividend raised 11% to $0.50/quarter, fourth consecutive year of 10%+ increases. Debt/capital held at a conservative 18%. This is textbook mature-insurer capital return and it is the main mechanism of shareholder value here.
• Insider activity: the sampled Form 4s (all dated 2026-07-01/02) are routine director deferred-stock-unit awards (A-Award, price $0), i.e. board compensation — no discretionary open-market buying or selling signal either way. Neutral.
• Management's own guidance (half-weighted — their own book): AIG's Q1'26 earnings release (SEC 8-K, filed 2026-04-30) is a real earnings release and management's forward language is explicit: CEO Peter Zaffino says AIG is "on track to meet or exceed the financial objectives that we outlined at our Investor Day in March 2025" and expresses "confidence in the long-term outlook" via the fourth straight double-digit dividend hike. They emphasize continued "disciplined, profitable growth" and navigating "an increasingly complex global risk landscape." Weight this at half — it is management talking its own book, with no specific numeric guide in the release beyond the reaffirmation of Investor-Day targets. The hard evidence (87.3% combined ratio, +80% AATI/sh, 12.2% core ROE) is more persuasive than the adjectives.

10. Catalysts & what to watch

• Next earnings: 2026-08-06 (Q2'26; Street EPS $1.92, revenue ~$7.26B). The key lines: combined ratio (does it stay sub-90%?), accident-year combined ratio as adjusted (the cleanest read on underwriting), and NPW growth ex-FX and ex-Convex (organic pricing).
• Catastrophe experience: Q2/Q3 are hurricane/wildfire season — the single biggest swing factor for any given quarter. A benign cat year is the bull case; a heavy one is the bear.
• Prior-year reserve development: AIG's history includes reserve strengthening; watch for adverse development, which would undercut the "clean underwriting" thesis.
• Buyback pace + Corebridge sell-down: continued repurchases and monetization of the residual 5.6% Corebridge stake fund the EPS-accretion story.
• Commercial-rate cycle: signs the "hard market" in commercial P&C is softening would cap top-line and pricing power.

Thesis tripwires (what would change the call): combined ratio back above ~92% for two quarters; a material adverse reserve charge; buyback pace slowing sharply; or a soft-market pricing rollover in commercial lines.

11. Key risks

• Catastrophe & reserve risk (structural): a major hurricane/wildfire/earthquake year, or discovery that older casualty claims were under-reserved, can erase a year of profit in one quarter. This is the defining risk of a P&C insurer and it never goes away.
• Cyclicality: commercial P&C pricing is cyclical; the current hard market that flatters results will eventually soften.
• Modest ROE: ~12% core ROE is the honest ceiling on quality — this is not a high-return franchise, which is why it trades near book.
• Investment-income sensitivity: results depend partly on the investment portfolio; rate moves and equity/Corebridge marks add GAAP noise (net investment income was −36% GAAP in Q1'26).
• Slow growth / value-trap risk: cheap can stay cheap. The 12-month −7.5% return (vs SPY +20.6%) shows the market has not rewarded the turnaround; there is no guarantee it re-rates.
• Thin conviction: Synthos has near-zero independent expert coverage on AIG — the call leans on quant/fundamentals and the Street, with less of a differentiated edge than our high-breadth names.

12. Verdict, position sizing & monitoring

Watch. AIG is a genuinely cheap, improving property-casualty insurer — 87.3% combined ratio, +80% AATI/share, 12.2% core ROE, 1.06× book, ~9× forward earnings, a growing 2.3% dividend, and disciplined buybacks. That is a respectable value/income setup, and our ~$88 base case (+11%) sits right on top of the Street. But it is not a Synthos-style conviction buy: growth is modest and decelerating, ROE is only low-double-digit, expert coverage is essentially absent, the stock has badly lagged the market for a year, and cat/reserve risk sits permanently in the tail. There is no exponential engine here, and no differentiated edge in our KB to justify more than a Watch.

• Sizing: if owned, a value/income satellite at ~1–3%, not a core position. This is a "buy-it-cheap-for-the-dividend-and-buyback" holding, best added on weakness (toward book value, ~$76), not chased.
• Monitoring: re-underwrite on the §10 tripwires — above all the combined ratio each quarter and any adverse reserve development; formal re-score each earnings print. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $79.39.
• Single biggest risk: a catastrophe or reserve shock that erases a year of the underwriting profit the whole thesis rests on.

Provenance & disclosures

• Traceability: 1 KB claim (we_study_billionaires-UoNHdafdlRo:592abe8bb9), breadth 1, and it is tangential (a tail-risk-insurance model analogy, not a direct AIG thesis). This verdict is fundamentals- and quant-driven; we did not manufacture conviction that does not exist. Fabricated conviction is structurally impossible (claim-ID reconciliation).
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · Q1'26 earnings release (SEC 8-K) 2026-04-30 · expert claim 2026-01-10. Forward figures are analyst consensus (FMP), labeled as estimates.
• Management caveat: AIG management guidance (§9) is management's own book, half-weighted by design; the release reaffirms March-2025 Investor-Day targets without a specific numeric guide.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").